Part of The Cleveland Clinic Foundation
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1999
No trial phase data available
No trial data available
No trial data available
No approval data available
- Post-hoc analysis of GATHER1 and GATHER2 trials reveals a clear structure-function relationship between ellipsoid zone integrity and visual acuity in geographic atrophy patients. - Patients with better vision exhibited greater preservation of ellipsoid zone integrity, with those having thicker EZ-RPE central subfield thickness showing more stable visual acuity over time. - Researchers suggest ellipsoid zone measurements could serve as early biomarkers to identify at-risk patients and guide clinical decision-making in geographic atrophy management.
- The HELIOS trial revealed OTX-TKI was well-tolerated with no serious adverse events, with all diabetic retinopathy severity score improvements occurring in the treatment arm and all worsening in the sham arm. - Post-hoc analysis using ultrawidefield fluorescein angiography showed reduced retinal leakage in OTX-TKI-treated patients, while sham group patients experienced worsening leakage across total retina, peripheral retina, and posterior pole. - Notably, vision-threatening complications were completely absent in the OTX-TKI treatment group, with researchers expressing optimism about tyrosine kinase inhibitors potentially providing sustained biological activity for 6-12 months.
